NCT00160316View on ClinicalTrials.gov

Endometrial Safety Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination

PHASE3CompletedINTERVENTIONAL
Enrollment

454

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Postmenopause
Interventions
DRUG

0.5 Mg Estradiol and 2.5 Mg Dydrogesterone

p.o. daily

Trial Locations (22)

Unknown

Site 10, Zagreb

Site 11, Zagreb

Site 12, Zagreb

Site 13, Zagreb

Site 32, Katowice

Site 30, Krakow

Site 35, Krakow

Site 36, Krakow

Site 34, Lublin

Site 31, Miechów

Site 33, Warsaw

Site 40, Bucharest

Site 41, Bucharest

Site 42, Bucharest

Site 43, Bucharest

Site 44, Bucharest

Site 45, Bucharest

Site 24, Donetsk

Site 20, Kiev

Site 21, Kiev

Site 22, Kiev

Site 23, Zaporizhzhya

All Listed Sponsors
lead

Solvay Pharmaceuticals

INDUSTRY

NCT00160316 - Endometrial Safety Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination | Biotech Hunter | Biotech Hunter